Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

Susvimo™, Breakthrough Therapy Discovered for Wet Age-Related Macular Degeneration (nAMD)

Roche discovered breakthrough therapy Susvimo™ (ranibizumab injection) for the treatment of people with neovascular or ‘wet’ age-related macular degeneration (nAMD).

Susvimoearlier known as port delivery system with ranibizumab is the first and only alternative treatment in 15 years which provides standard-of-care eye injections which requires often in a month.

Susvimo is delivered to eye through refillable implant. The implant is inserted into the eye during a one-time, outpatient procedure and refilled every six months. It helps people with nAMDto maintain their vision as few as two treatments per year. It provides as an alternative to anti-VEGF eye injections by delivering susvimocontinuously.

With the advancements in treatment, Susvimo plays as a new treatment option for patients with wet AMD.

U.S. Food and Drug Administration (FDA) approves Susvimo™, as a first-of-its-kind therapeutic approach for neovascular or ‘wet’ age-related macular degeneration (nAMD).

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinRehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024